Elektrofi Inc., a biopharmaceutical delivery technology company, has closed an upsized $112.25 million Series C financing. The round was co-led by Novo Holdings, RA Capital Management, Royalty Pharma, SR One, and TPG Life Sciences Innovations, with participation from Eli Lilly and Company and other prominent life science investors.   The fresh capital will be used to establish Phase 3 and commercial-scale Good Manufacturing Practice (GMP) manufacturing lines. This expansion, coupled with the c...